Cargando…
KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine
Precision medicine for Mendelian epilepsy is rapidly developing. We describe an early infant with severely pharmacoresistant multifocal epilepsy. Exome sequencing revealed the de novo variant p.(Leu296Phe) in the gene KCNA1, encoding the voltage‐gated K(+) channel subunit K(V)1.1. So far, loss‐of‐fu...
Autores principales: | Müller, Peter, Takacs, Danielle S., Hedrich, Ulrike B. S., Coorg, Rohini, Masters, Laura, Glinton, Kevin E., Dai, Hongzheng, Cokley, Jon A., Riviello, James J., Lerche, Holger, Cooper, Edward C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109319/ https://www.ncbi.nlm.nih.gov/pubmed/36793218 http://dx.doi.org/10.1002/acn3.51742 |
Ejemplares similares
-
De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy
por: Syrbe, Steffen, et al.
Publicado: (2015) -
KCNA2-Related Epileptic Encephalopathy
por: Kearney, Jennifer A.
Publicado: (2015) -
Complete loss of KCNA1 activity causes neonatal epileptic encephalopathy and dyskinesia
por: Verdura, Edgard, et al.
Publicado: (2020) -
Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1-Associated Episodic Ataxia and a Comprehensive Review of the Literature
por: Lauxmann, Stephan, et al.
Publicado: (2021) -
A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine
por: Imbrici, Paola, et al.
Publicado: (2021)